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#Appendix 1.
Guillain-Barre´ syndrome is a heterogeneous disorder regarding the clinical presentation, electrophysiological subtype and outcome.
Previous single country reports indicate that Guillain-Barre´ syndrome may differ among regions, but no systematic comparative
studies have been conducted. Comparative studies are required to identify factors determining disease susceptibility, variation and
prognosis, and to improve diagnostic criteria. The International Guillain-Barre´ Syndrome Outcome Study is a prospective, observa-
tional cohort study including all patients within the diagnostic spectrum, aiming to describe the heterogeneity of Guillain-Barre´
syndrome worldwide. The current study was based on the ﬁrst 1000 inclusions with a follow-up of at least 1 year and conﬁrmed the
variation in clinical presentation, course and outcome between patients. The full clinical spectrum of Guillain-Barre´ syndrome was
observed in patients from all countries participating in the International Guillain-Barre´ Syndrome Outcome Study, but the frequency
of variants differed between regions. We compared three regions based on geography, income and previous reports of Guillain-Barre´
syndrome subtypes: ‘Europe/Americas’, ‘Asia’ (without Bangladesh), and ‘Bangladesh’. We excluded 75 (8%) patients because of
alternative diagnoses, protocol violations, or missing data. The predominant clinical variant was sensorimotor in Europe/Americas
(n = 387/562, 69%) and Asia (n = 27/63, 43%), and pure motor in Bangladesh (n = 74/107, 69%). Miller Fisher syndrome and
Miller Fisher-Guillain-Barre´ overlap syndrome were more common in Asia (n = 14/63, 22%) than in the other two regions (Europe/
Americas: n = 64/562, 11%; Bangladesh: n = 1/107, 1%) (P5 0.001). The predominant electrophysiological subtype was demyeli-
nating in all regions (Europe/Americas: n = 312/573, 55%; Asia: n = 29/65, 45%; Bangladesh: n = 38/94, 40%). The axonal subtype
occurred more often in Bangladesh (n = 34/94, 36%) than in Europe/Americas (n = 33/573, 6%) and other Asian countries (n = 4/
65, 6%) (P5 0.001). In all regions, patients with the axonal subtype were younger, had fewer sensory deﬁcits, and showed a trend
towards poorer recovery compared to patients with the demyelinating subtype. The proportion of patients able to walk unaided after
1 year varied between Asia (n = 31/34, 91%), Europe/Americas (n = 334/404, 83%) and Bangladesh (n = 67/97, 69%) (P = 0.003).
A similar variation was seen for mortality, being higher in Bangladesh (n = 19/114, 17%) than in Europe/Americas (n = 23/486, 5%)
and Asia (n = 1/45, 2%) (P5 0.001). This study showed that factors related to geography have a major inﬂuence on clinical
phenotype, disease severity, electrophysiological subtype, and outcome of Guillain-Barre´ syndrome.
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Introduction
Guillain-Barre´ syndrome (GBS) is an acute polyradiculo-
neuropathy that yearly affects 100000 people worldwide
(Sejvar et al., 2011a). While GBS is an established clinical
syndrome with deﬁned diagnostic criteria (Asbury and
Cornblath, 1990; Sejvar et al., 2011b), patients differ con-
siderably in clinical presentation, disease course, and out-
come. Patients may have clinical variants of GBS,
including Miller Fisher syndrome (MFS) and pure motor,
paraparetic, or pharyngeal-cervical-brachial forms (Willison
et al., 2016). The electrophysiological characteristics of GBS
are likewise heterogeneous and include two major subtypes
with demyelinating or axonal features (Willison et al., 2016).
Some patients are mildly affected and recover spontaneously,
but others develop tetraplegia and respiratory or autonomic
failure requiring intensive care and remain severely disabled
or die despite treatment (van den Berg et al., 2014). The
time to improvement is reduced with plasma exchange or
intravenous immunoglobulin (IVIg) (Hughes et al., 2007,
2014; Chevret et al., 2017) but most patients in low-
income countries receive supportive care only (Islam et al.,
2016).
Comparison of previous studies conducted in single coun-
tries suggests that the variation of GBS may be inﬂuenced by
factors related to the geographical origin of patients, such as
endemic infections or unusual epidemics like the recent GBS
peaks related to Zika virus (Cao-Lormeau et al., 2016; Parra
et al., 2016). These studies illustrate a wide variability in
prevalence of clinical variants and electrophysiological sub-
types of GBS between regions, suggesting that sensorimotor
and demyelinating GBS predominate in Europe and North
America, whereas pure motor and axonal GBS are more
frequent in Asian and South American countries (Lyu
et al., 1997; Hadden et al., 1998; Bogliun et al., 2004;
Hughes and Cornblath, 2005; Islam et al., 2010; Sekiguchi
et al., 2012; Kuwabara and Yuki, 2013; Mitsui et al., 2015;
Willison et al., 2016; Liu et al., 2018). However, these single
country studies had different study designs, inclusion criteria
and deﬁnitions of GBS variants (Ho et al., 1995; Hadden
et al., 1998). Therefore, although valuable, these studies
have intrinsic limitations and do not describe the full spec-
trum and geographical variation of GBS. Demonstrating the
geographical variation is required to clarify the role of en-
vironmental and host factors in severity and subtypes of
GBS, and point to the need for different diagnostic criteria
and treatments in various parts of the world.
The International GBS Outcome Study (IGOS) is a multi-
centre, prospective, observational cohort study investigating
factors that determine and predict the clinical course, sub-
type, and outcome of GBS (Jacobs et al., 2017). The aim of
the current study was to use the collected data from the ﬁrst
1000 patient inclusions in IGOS with a follow-up of 1 year
to describe the heterogeneity of GBS and to compare the
clinical presentation, electrophysiological subtypes, disease
course, and outcome between patients from different geo-
graphical regions.
Materials and methods
This study is registered at ClinicalTrials.gov with identiﬁer:
NCT01582763
Study design
The IGOS study protocol has been described elsewhere (Jacobs
et al., 2017). The current study was based on the analysis
of the ﬁrst 1000 included patients. Patients fulﬁlled diagnostic
criteria for GBS or its variants and were included within
2 weeks from onset (Asbury and Cornblath, 1990; Sejvar
et al., 2011b; Wakerley et al., 2014). Patients were enrolled
between May 2012 and July 2015 from 135 active study sites
in 18 countries across ﬁve continents. The study was approved
by the review boards of Erasmus University Medical Centre,
Rotterdam, The Netherlands, and the local institutional review
boards of participating hospitals or universities. Written in-
formed consent was obtained from all patients.
Data collection
Data were collected regarding demography, antecedent events,
and neurological symptoms and signs of GBS at study entry
and at 1, 2, 4, 8, 13, 26 and 52 weeks (Jacobs et al., 2017).
Muscle strength was recorded by the Medical Research
Council (MRC) score (Kleyweg et al., 1991) and disability
by the GBS disability score (Hughes et al., 1978). Presence
of autonomic dysfunction, deﬁned as cardiac, blood pressure,
gastro-enteric, bladder, pupil, or other (e.g. excessive perspir-
ation) abnormalities, was left to the decision of the treating
physician. Results of routine CSF examination and nerve con-
duction studies (NCS) were collected. We deﬁned an elevated
CSF protein level as 40.45 g/l (Hadden et al., 2001; Jacobs
et al., 2017). A cytoalbuminological dissociation was deﬁned
as a CSF cell count 550 cells/ml combined with a CSF protein
level 40.45 g/l. To determine the electrophysiological subtype,
we used raw data of the ﬁrst NCS, local reference values, and
an algorithm to classify each NCS into demyelinating, axonal,
inexcitable, equivocal, or normal subtype, according to criteria
of Hadden et al. (1998). Patients with axonal and demyelinat-
ing neuropathy were compared for each region, to specify pre-
viously reported differences between these subtypes.
Disease nadir was deﬁned by the lowest MRC sum score
during the ﬁrst 4 weeks from study entry. When two visits
had equal lowest MRC sum scores, the ﬁrst visit score was
used. Patients who had reached nadir before study entry and
patients lost to follow-up in the ﬁrst 4 weeks were excluded
from the analysis of nadir.
Asymmetrical weakness was deﬁned as a difference in MRC
sum scores of 55 points between the right- versus left-sided
muscles (Fokke et al., 2014).
Clinical variants were adopted from the reported variants at
visit Week 2, substantiated by recorded data, and were deﬁned
as: (1) sensorimotor; (2) pure motor; (3) MFS or MFS-GBS
overlap syndrome; and (4) other, which included pure sensory,
ataxic, and pharyngeal-cervical-brachial (Wicklein et al., 1997;
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van den Berg et al., 2014; Wakerley et al., 2014; Willison
et al., 2016).
Local treating physicians registered clinical ﬂuctuations.
We additionally checked the data for ﬂuctuations deﬁned as a
deterioration in MRC sum score 45 points and/or a deterior-
ation on the GBS disability scale 51 point(s) during two con-
secutive visits, not caused by non-GBS related complications,
within the ﬁrst year of follow-up. A deterioration on the GBS
disability scale from 0 (‘a healthy state’) to 1 (‘minor symp-
toms’) was not considered a ﬂuctuation. When MRC sum
score, GBS disability score and information on clinical ﬂuctu-
ations were missing for two or more consecutive visits, the oc-
currence of a ﬂuctuation was considered undeterminable.
When patients received multiple immunomodulating treat-
ments (i.e. combinations of IVIg and plasma exchange), we
used the ﬁrst administered therapy for the treatment analysis.
The primary endpoints for clinical outcome were the ability
to walk independently (GBS disability score 42) at 6 and
12 months. Patients who were lost to follow-up at or after
26 and 52 weeks, or who had a missed visit and were able
to walk independently at the previous visit, were considered to
have reached this endpoint.
Geographical regions
To determine geographical inﬂuence on the variation of GBS,
we subdivided patients into three different regions: ‘Europe/
Americas’ (including Argentina, Belgium, Canada, Denmark,
France, Germany, Greece, Italy, Spain, The Netherlands, UK,
and USA), ‘Asia’ (including Japan, Malaysia, and Taiwan),
and ‘Bangladesh’. These regions were based on previously re-
ported prevalences of clinical variants and electrophysiological
subtypes of GBS, national income level (World Bank, 2017),
availability or affordability of speciﬁc immunotherapy with
standard of supportive care, and geographical location of the
participating countries. Europe and Americas were initially
considered two separate regions based on their geographical
location, but were later combined because of great similarity of
the other determinative variables. The Asian group consisted
only of high-income countries with good quality medical ser-
vices and availability of treatment. For this study, we excluded
patients from Africa (n = 11) and Australia (n = 4) from the
geographical analysis because of small patient numbers.
Statistical analysis
We used SPSS Statistics 21.0 for data analysis. Continuous
data are presented as medians with interquartile ranges
(IQR) and dichotomized or categorical data as numbers and
proportions. We used the Mann-Whitney U-test and Kruskal-
Wallis test to compare continuous data, and the 2-test or
Fisher’s exact test to compare proportions. Kaplan-Meier
analysis was used to present the proportion of participants
able to walk independently during follow-up. A two-sided
P-value5 0.05 was considered signiﬁcant. P-values reﬂect
comparisons of the three regions, unless stated otherwise.
Data availability
Data collected in IGOS will be used initially for planned
research projects conducted by the IGOS Consortium. Some
data will be made available from the corresponding author,
upon reasonable request. The data are not publicly available
because they contain information that could compromise the
privacy of our patients.
Results
We excluded 62 (6%) patients from analysis because of al-
ternative diagnosis: acute onset chronic inﬂammatory demye-
linating polyneuropathy (n = 37), other peripheral neuropathy
(n = 8), CNS disorder (n = 12), functional disorder (n = 2), or
disorder not speciﬁed (n = 3). We excluded ﬁve patients be-
cause of protocol violations, and eight patients because of
insufﬁcient data. The remaining cohort of 925 patients origi-
nated from Argentina (n = 43), Australia (n = 4), Bangladesh
(n = 125), Belgium (n = 16), Canada (n = 25), Denmark
(n = 76), France (n = 27), Germany (n = 45), Greece (n = 4),
Italy (n = 82), Japan (n = 36), Malaysia (n = 28), The
Netherlands (n = 67), South Africa (n = 11), Spain (n = 76),
Taiwan (n = 5), UK (n = 129), and USA (n = 126). At 1
year, 143 (16%) patients were lost to follow-up.
Cohort description and
heterogeneity of GBS
GBS occurred in all age categories with an overall median
age of 51 years (IQR 33–64, range 6 months to 88 years)
(Fig. 1). The number of patients increased with age
and reached its peak at the age categories of 50–59 and
60–69 years. Males predominated in all age categories with
an overall male to female ratio of 1.5.
An antecedent event in the 4 weeks before neurological
onset was reported in 649 (76%) patients, mainly upper re-
spiratory tract infections (35%) and gastroenteritis (27%). At
study entry, 677 (73%) patients had tetraparesis, 105 (11%)
had paraparesis, and 19 (2%) had upper limb weakness only.
During follow-up, 22 (21%) patients who presented with
paraparesis and three (16%) patients who presented with
sole weakness of upper limbs also developed tetraparesis.
Only ﬁve patients had asymmetrical limb weakness.
Figure 1 Age and gender distribution of IGOS cohort.
*P5 0.05 for difference in number of males and females per age
category. n = 919.
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The median time from onset of symptoms to study entry
was 6 days (IQR 3–9). Nadir was reached within 2 weeks
in 824 (96%) patients, and within 4 weeks in 858 (99.8%)
patients. One patient continued to deteriorate until Week 8
and another until Week 13. At nadir, the median MRC
sum score was 44 (IQR 25–53), which was 2 points
lower than at entry (46, IQR 33–54) (Wilcoxon signed
ranks test P5 0.001).
The clinical course deﬁned by the GBS disability score
was highly variable (Fig. 2). For those unable to walk in-
dependently at nadir, 439 (77%) regained the ability
to walk independently at 6 months, and 445 (81%) at
12 months. Overall, 19% required mechanical ventilation
during the disease course. Seven per cent died during
follow-up, and the median time from onset of weakness
to death was 33 days (IQR 16–88, range 6–280) (Table 1).
CSF was examined in 823 (89%) patients within a median
time of 4 days (IQR 2–8) from onset of neurological symp-
toms. Elevated CSF protein level was detected in 561 (68%)
of these patients. The CSF protein level was strongly inﬂu-
enced by the timing of the lumbar puncture: only 50% had
an elevated CSF protein level when tested within 3 days
from onset of neurological symptoms, compared to 84%
when tested after 7 days. Median CSF protein level in the
early group was 0.45 g/l (IQR 0.33–0.73), and in the late
group 0.98 g/l (IQR 0.59–1.84) (P5 0.001). Most patients
had a normal CSF leucocyte count (55 cells/ml) (n = 641,
80%). A mildly elevated cell count (5–50/ml) was found in
149 (19%) patients, but 14 (2%) patients had more than 50
leucocytes/ml (range 53–232). No alternative diagnosis was
found during follow-up in these patients with CSF pleiocy-
tosis (450ml) despite extensive diagnostic work-up. Six
(43%) of these patients required mechanical ventilation,
compared to 148 of 790 (19%) patients without pleiocytosis
(P = 0.035), but the clinical course and outcome were similar
between the two groups. Cytoalbuminological dissociation
was present in 538 (67%) patients.
A nerve conduction study was performed in 829/862
(96%) patients, median 7 days (IQR 4–11) from onset of
weakness. In 84 (10%) of these patients, the NCS could
not be evaluated because of missing raw data or missing
local reference values. NCS of the remaining 745 patients
were classiﬁed as demyelinating (n = 390, 52%), axonal
(n = 71, 10%), inexcitable (n = 20, 3%), equivocal
(n = 215, 29%), or normal (n = 49, 7%). Compared to
the demyelinating group, patients with axonal GBS were
younger (31 years, IQR 20–56 versus 54 years, IQR 36–
67; P5 0.001) and more often reported preceding diar-
rhoea (24/71, 34% versus 85/390, 22%; P = 0.03).
Furthermore, patients with axonal GBS had more severe
limb weakness at both study entry (MRC sum score 33,
IQR 14–44 versus 46, IQR 34–54; P50.001) and nadir
(19, IQR 5–41 versus 42, IQR 24–51; P5 0.001). At
6 months, 31/50 (62%) patients with axonal neuropathy
were able to walk independently, versus 216/262 (82%) in
the demyelinating group (P = 0.001). At 12 months, 34/47
(72%) with axonal GBS and 220/252 (87%) with demye-
linating GBS were able to walk independently (P = 0.01).
Geographical variation of GBS
The demography, antecedent events, clinical presentation,
electrophysiological subtypes, diagnostic ﬁndings, treatment
and outcome of GBS were compared between ‘Europe/
Americas’ (n = 715), ‘Asia’ (n = 69), and ‘Bangladesh’
(n = 125) (Tables 2, 3, Figs 3A, B, 4 and Supplementary
Table 1).
Patients from Bangladesh were signiﬁcantly younger (age
28 years, IQR 16–40) than patients from Europe/Americas
(55 years, IQR 37–67, P5 0.001) and Asia (50 years, IQR
34–60, P5 0.001). An upper respiratory tract infection
was the most common reported antecedent event in
Europe/Americas (38%) and Asia (51%), whereas in
Bangladesh, gastroenteritis was predominant (36%).
Patients from Bangladesh had more severe muscle weakness
than patients from the other two regions at study entry and
nadir. Sensory deﬁcits were more frequent in patients from
Europe/Americas than in patients from the other two re-
gions. Cranial nerve involvement was more frequent in pa-
tients from Asia and Bangladesh than in patients from
Europe/Americas. In Asia, more patients had oculomotor
weakness, whereas in Bangladesh the proportion of patients
with bulbar weakness was signiﬁcantly higher than in the
other regions.
Patients from Asia reported pain less frequently than pa-
tients from Europe/Americas and Bangladesh. Seventy-
seven (62%) of 125 patients from Bangladesh reported
pain at study entry, of whom 73 (95%) had either
Figure 2 Clinical course during 1-year follow-up.
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muscle or joint pain, also including patients with a pure
motor variant. Patients from Europe/Americas were less
frequently ventilated (17%) than patients from Asia
(25%, P = 0.13) and Bangladesh (29%, P = 0.003).
The predominant clinical pattern of GBS in Europe/
Americas and Asia was sensorimotor (Europe/Americas:
n = 387, 69%; Asia n = 27, 43%), whereas in Bangladesh
most patients had pure motor GBS (n = 74, 69%). MFS or
MFS-GBS overlap occurred more frequently in Asia
(n = 14, 22%) than in Europe/Americas (n = 57, 11%)
and Bangladesh (n = 1, 1%) (P5 0.001).
Considerable variation was observed in treatment of GBS
between regions. IVIg was the most common treatment for
patients from Europe/Americas (n = 612, 86%) and Asia
(n = 50, 73%), whereas in Bangladesh the majority of pa-
tients (n = 108, 86%) received no immunomodulating
therapy.
The median time to regain the ability to walk independ-
ently was 63 days (IQR 28–186) in Europe/Americas, 39
days (IQR 17–94) in Asia, and 95 days (IQR 36–190) in
Bangladesh (P = 0.002). The proportion of patients who
regained the ability to walk independently after 12
months follow-up was 69% in Bangladesh, 83% in
Europe/Americas, and 91% in Asia (P = 0.003; Tables 2,
3 and Fig. 4). Mortality was signiﬁcantly higher in
Bangladesh (n = 19, 17%) than in Europe/Americas
(n = 23, 5%, P5 0.001) and Asia (n = 1, 2%, P = 0.02).
The predominant electrophysiological subtype was
demyelinating for all regions (Europe/Americas: n = 312,
55%; Asia: n = 29, 45%; Bangladesh: n = 38, 40%). The
axonal subtype occurred more often in Bangladesh (n = 34,
36%). Clinical differences among electrophysiological sub-
types were compared for each region (Supplementary Table
2). In all three regions, patients with the axonal subtype
Table 1 Demographics and clinical features of IGOS
cohort (n = 925)
Demographics
Age, years (IQR) 51 (33–64)
Male:female ratio 552/373 (1.48)
Clinical features at entry
Antecedent events (%)
URTI 303/857 (35)
Gastroenteritis 229/857 (27)
Othera 117/857 (14)
None 208/857 (24)
Severity and distribution of weakness (%)
MRC sum score, possible range 0–60b (IQR) 46 (32–54)
Tetraparesis 677/924 (73)
Weakness lower limbs only 105/924 (11)
Weakness upper limbs only 19/924 (2)
Unilateral limb weakness 10/924 (1)
Otherc 15/924 (2)
No limb weakness 98/924 (11)
Sensory deficits (%) 543/890 (59)
Cranial nerve involvement (%) 464/922 (50)
Oculomotor weakness 139/922 (15)
Facial weakness 286/922 (31)
Bulbar weakness 234/922 (25)
Reflexes upper limbsd (%)
Areflexia 541/920 (59)
Hyporeflexia 259/920 (28)
Normoreflexia 108/920 (12)
Hyperreflexia 12/920 (1)
Reflexes lower limbsd (%)
Areflexia 704/920 (77)
Hyporeflexia 182/920 (20)
Normoreflexia 18/920 (2)
Hyperreflexia 16/920 (2)
Autonomic dysfunction (%) 228/924 (25)
Pain (%) 506/923 (55)
Time from onset of weakness to admission, days
(IQR)
3 (2–6)
Clinical features at nadir
Severity and distribution of weakness (%)
MRC sum score, possible range 0–60b (IQR) 44 (25–53)
Tetraparesis 629/816 (77)
Weakness lower limbs only 82/816 (10)
Weakness upper limbs only 16/816 (2)
Unilateral limb weakness 8/816 (1)
Otherc 11/816 (1)
No limb weakness 70/816 (9)
GBS disability score (%)
Healthy, 0 1/815 (0.1)
Minor symptoms but able to run, 1 27/815 (3)
Able to walk independently, unable to run, 2 144/815 (18)
Not able to walk independently for at least 10 m,
3
159/815 (20)
Bedridden or wheelchair bound, 4 359/815 (44)
Mechanically ventilated for at least part of the day,
5
125/815 (15)
Clinical course
GBS variant after 2-week follow-up (%)
Sensorimotor 453/744 (61)
(continued)
Table 1 Continued
Pure motor 170/744 (23)
MFS 40/744 (5)
MFS-GBS overlap 39/744 (5)
Othere 42/744 (6)
Fluctuations in clinical coursef (%)
Monophasic course 615/700 (88)
Fluctuations during first 8 weeks 60/700 (9)
Fluctuations after first 8 weeks 16/700 (2)
Fluctuations during and after first 8 weeks 9/700 (1)
Ventilator dependency (%) 176/925 (19)
Mortality (%) 44/659 (7)
Data are presented as n (%) or median (IQR). URTI = upper respiratory tract infection.
aOther antecedent events: urinary tract infection, vaccination, surgery and other.
bLarger score indicates greater muscle strength.
cOther patterns of weakness (e.g. asymmetrical weakness).
dReflexes in both paretic/paralytic and normal strength limbs.
eOther clinical variants: pharyngo-cervical-brachial, pure sensory, ataxic or other
variant.
fFluctuations defined as a decrease in the MRC sum score of 45 points and/or
an increase in the GBS disability score of 51 points, excluding fluctuations
caused by complications not related to GBS (e.g. fractures, shin splint (medial tib-
ial stress syndrome), pain, etc.). Changes in GBS disability score from 0 to 1 were
not included.
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were younger than patients with the demyelinating subtype.
Sensory deﬁcits at entry and nadir were less frequent in
patients with axonal neuropathy. There was a trend to-
wards a lower MRC sum score at study entry and nadir
(only signiﬁcant for Europe/Americas), and poorer outcome
at 6 and 12 months in the axonal groups compared to the
demyelinating groups (Supplementary Table 2).
Discussion
Our study demonstrates the marked worldwide variation of
GBS with respect to clinical variants, severity, electro-
physiological subtypes, and outcome. This variation is
inﬂuenced by regional differences in demography, preced-
ing events, and treatment.
Table 2 Differences in GBS between geographical regions
Region
Europe/Americas (n = 715) Asia (n = 69) Bangladesh (n = 125) P-value
Demographics
Age, years (IQR) 55 (37–67) 50 (34–60) 28 (16–40) _0.001
Male/female ratio (%) 418/297 (1.41) 42/27 (1.56) 84/41 (2.05) 0.18
Clinical features at entry
MRC sum score, possible range 0–60a (IQR) 48 (38–56) 49 (40–58) 22 (7–37) _0.001
Sensory deficits (%) 463/686 (65) 37/68 (54) 35/120 (28) _0.001
Cranial nerve involvement (%) 330/712 (46) 44/69 (64) 84/125 (67) _0.001
Oculomotor weakness 106/712 (15) 26/69 (38) 5/125 (4) _0.001
Facial weakness 220/712 (31) 28/69 (41) 32/125 (26) 0.10
Bulbar weakness 142/712 (20) 23/69 (33) 64/125 (51) _0.001
Autonomic dysfunction (%) 189/714 (27) 7/69 (10) 28/125 (22) 0.01
Pain (%) 415/713 (58) 8/69 (12) 77/125 (62) _0.001
Time from onset of weakness to admission, days (IQR) 3 (2–6) 4 (2–6) 4 (2–8) 0.01
Clinical features at nadir
MRC sum score, possible range 0–60a (IQR) 46 (30–54) 48 (34–58) 16 (3–32) _0.001
GBS disability score (%)
Unable to walk independently (42) 478/626 (76) 50/66 (76) 100/107 (93) _0.001
Sensory deficits (%) 408/588 (69) 37/63 (59) 29/100 (29) _0.001
Cranial nerve involvement (%) 304/620 (49) 44/65 (68) 73/107 (68) _0.001
Oculomotor weakness 84/620 (14) 25/65 (39) 5/107 (5) _0.001
Facial weakness 220/620 (36) 31/65 (48) 32/107 (30) 0.06
Bulbar weakness 136/620 (22) 24/65 (37) 57/107 (53) _0.001
Autonomic dysfunction (%) 184/626 (29) 11/66 (17) 30/107 (28) 0.09
Pain (%) 354/625 (57) 11/66 (17) 67/107 (63) _0.001
Ventilator dependency (%) 121/715 (17) 17/69 (25) 36/125 (29) 0.004
Electrophysiology classification (%)
Demyelinating 312/573 (55) 29/65 (45) 38/94 (40) 0.02
Axonal 33/573 (6) 4/65 (6) 34/94 (36) _0.001
Inexcitable 10/573 (2) 1/65 (2) 9/94 (10) _0.001
Equivocal 182/573 (32) 20/65 (31) 12/94 (10) 0.001
Normal 36/573 (6) 11/65 (17) 1/94 (1) _0.001
Initial treatment (%)
None 54/715 (7) 9/69 (13) 108/125 (86) _0.001
IVIg 612/715 (86) 50/69 (73) 7/125 (6) _0.001
PE 43/715 (6) 10/69 (15) 9/125 (7) 0.03
Otherb 6/715 (1) 0/69 (0) 1/125 (1) 0.75
Time from onset of weakness to treatment, days (IQR) 4 (2–7) 5 (3–7) 7 (5–12) 0.003
Outcome
Median time to independent walking, days (IQR) 63 (28–186) 39 (17–94) 95 (36–190) 0.002
Able to walk independently at 6 months (%) 331/418 (79) 36/41 (88) 60/97 (62) _0.001
Able to walk independently at 12 months (%) 334/404 (83) 31/34 (91) 67/97 (69) 0.003
Mortality
Patients deceased at 12 months (%) 23/486 (5) 1/45 (2) 19/114 (17) _0.001
Data are presented as n (%) or median (IQR). P-values represent a comparison between the three regions. P-values below 0.05 are highlighted in bold. PE = plasma exchange.
aLarger score indicates greater muscle strength.
bOther treatment: steroids, immunoadsorption and trial medication.
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In all three regions, the frequency of GBS increased with
age, for both males and females. Similar age distributions
for GBS have been found previously (McGrogan et al.,
2009; Sejvar et al., 2011a). Patients from Bangladesh
were younger than patients from the other two regions,
which corresponds to results from a previous study in
Bangladesh, where the median age was 21 years (range
2–65) (Islam et al., 2010). The regional differences in age
distribution may be explained by the variation in demog-
raphy of the general populations and merely reﬂect the
relative number of persons at risk in each age category
per region (UN, http://data.un.org). Males were more fre-
quently affected than females in a ratio of 1.5:1, in all age
categories and regions. Similar male to female ratios have
been reported previously (Hughes and Cornblath, 2005;
van den Berg et al., 2014). Therefore, male gender and
higher age are independent risk factors for developing
GBS worldwide.
The full clinical spectrum of GBS was observed in pa-
tients from all countries participating in IGOS, but the fre-
quency of variants differed considerably between regions.
The predominant variant in Europe/Americas was sensori-
motor, whereas in Bangladesh pure motor GBS predomi-
nated. The proportion of patients with MFS or MFS-GBS
overlap syndrome was higher in Asia than in the other two
regions. A similar distribution of clinical variants per region
has been suggested in previous reports from single coun-
tries. In these studies, the frequency of pure motor GBS
ranged from 10–18% in Europe (Visser et al., 1995) to
as high as 92% in Bangladesh (Islam et al., 2010). The
frequency of MFS varied from 3% in Europe (Lo, 2007)
to 34% in Eastern Asia (Mori et al., 2001; Mitsui et al.,
2015). The clinical presentation of the patients in the IGOS
cohort was similar to previous studies from single countries
in Europe/Americas (Fokke et al., 2014), Asia (Matsui
et al., 2018) and Bangladesh (Islam et al., 2016; Ishaque
et al., 2017).
Almost all patients reached nadir within 4 weeks after
study entry (99.8%), and 96% of patients even within
2 weeks. In another study, 3% of the patients reached
nadir between 4 and 6 weeks (Fokke et al., 2014). While
a progressive phase of more than 4 weeks could be re-
garded as an exception, subacute inﬂammatory demyelinat-
ing polyradiculoneuropathy should be considered in these
patients, a previously described intermediate form between
GBS and chronic inﬂammatory demyelinating polyradiculo-
neuropathy (Hughes et al., 1992). At the other end of the
GBS spectrum, patients reached clinical nadir within days.
Figure 3 Clinical variants (Week 2) (A) and antecedent events (B) in different geographical areas. (A) MFS: Miller Fisher and Miller
Fisher GBS overlap syndromes. Other: pharyngeal-cervical-brachial, pure sensory, ataxic and other clinical variants. (B) Other: urinary tract
infection, vaccination, surgery and other antecedent events. URTI = upper respiratory tract infection.
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Some patients already had inexcitable nerves at ﬁrst NCS.
The mechanism of nerve inexcitability is unknown but may
be mediated by early loss of axonal or myelin structural
integrity or by functional block at the nodes of Ranvier or
nerve terminals, caused by anti-nerve antibodies, ionic im-
balance, or other inﬂammatory mediators.
Demyelinating and axonal subtypes of GBS were seen in
all participating countries but the frequencies varied be-
tween regions. The demyelinating subtype was the predom-
inant subtype in all regions. However, in Bangladesh a
substantial proportion of patients had axonal neuropathy.
These ﬁndings are in line with results from previous studies,
where demyelinating GBS was found in 60–80% of North
American and European patients (Hadden et al., 1998; van
den Berg et al., 2014). Axonal GBS was reported in 3–17%
in Europe (Hadden et al., 1998; Sekiguchi et al., 2012;
Kuwabara and Yuki, 2013), in 23–65% in Asia
(Kuwabara and Yuki, 2013; Mitsui et al., 2015), and up
to 67% in Bangladesh (Islam et al., 2010). Interestingly, in
all three regions patients with axonal GBS were younger
than patients with demyelinating GBS. The inﬂuence of
electrophysiological subtype on prognosis is under debate,
as recovery in axonal GBS can be slow and incomplete due
to axonal degeneration, or faster due to resolving transient
conduction blocks, and may depend upon the subtype cri-
teria (Kuwabara and Yuki, 2013; van den Berg et al.,
2014). The current study showed that the axonal subtype
was signiﬁcantly associated with poor recovery in the full
cohort and a similar trend was observed in the subgroup
analysis per region (Supplementary Table 2). The associ-
ation between axonal GBS and younger age may reduce
the effect of axonal involvement on poor recovery.
Further analysis of NCS and other prognostic factors is
required to determine the association between GBS subtype
and outcome.
The regional differences in frequencies of clinical and
electrophysiological subforms of GBS may be explained
in part by the variation in local exposure to infections.
The frequency of patient-reported gastroenteritis in our
cohort ranged from 25% in Europe/Americas to 36% in
Bangladesh. Previous studies have shown an association
between preceding gastroenteritis and pure motor and
axonal GBS (Islam et al., 2010; Kuwabara and Yuki,
2013). Campylobacter jejuni is the predominant cause
of gastroenteritis preceding GBS worldwide, but previous
reports suggest that the frequency of this infection may
differ substantially among regions. The association be-
tween preceding C. jejuni infection and axonal GBS is
related to the induction of cross-reactive antibodies to
gangliosides (Willison et al., 2016). A recent retrospective
study indicated a relatively high frequency of the demye-
linating subtype (49%) and lower frequency of the axonal
subtype (19%) in Southern China (Liu et al., 2018), while
previous studies from Northern China from the 1990s
reported the axonal subtype in 65% of GBS patients
(Ho et al., 1995). It is unknown whether this variation
represents a regional difference within China or a change
in GBS spectrum over time in parallel to changes in ex-
posure to infections, especially with C. jejuni (Baker
et al., 2012; Liu et al., 2018). Future serological studies
will investigate the role of preceding infections, and
immune responses to these infections, to explain the re-
gional differences.
The clinical course and outcome varied substantially
among the three regions. The best outcome was observed
in Asia, in part related to the higher frequency of MFS in
that region (Mori et al., 2001; Mitsui et al., 2015). The
worst outcome was found in Bangladesh, despite the
younger age of these patients. Several factors previously
associated with poor prognosis were more frequent in
Bangladesh, such as the frequency of preceding gastroenter-
itis, axonal subtype, and more severe disease in the acute
stage. Most importantly, only 13% of the patients in
Bangladesh received plasma exchange or IVIg and the facil-
ities for supportive care were limited.
Although this study is the largest prospective study on
GBS so far, there are several limitations. First, IGOS
aimed to include the full spectrum of GBS, irrespective
of age, disease severity, and treatment, but referral bias
probably favoured inclusion of patients with more severe
disease that required hospitalization and treatment.
Participating centres were mostly tertiary care hospitals
with speciﬁc neuromuscular expertise. It is unknown
Figure 4 Kaplan-Meier analysis of time to walk unaided in
different geographical areas. Kaplan-Meier analysis for patients
unable to walk unaided (GBS disability score4 2) at disease nadir.
Table 3 Kaplan-Meier analysis: numbers at risk
Numbers at risk at different
time points (days)
7 14 28 56 91 182
Europe/Americas 416 360 285 198 139 57
Asia 41 33 24 13 6 3
Bangladesh 92 81 64 51 34 19
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whether referral bias differed among countries and if this
might have inﬂuenced the observed regional differences.
Second, the number of inclusions varied per country and
several areas, especially Asia, Africa, and Australia, were
under-represented. The centre in Dhaka, Bangladesh, in
contrast, is the national and public tertiary care hospital
for GBS, which explains the high number of inclusions
and the high proportion of patients receiving supportive
care only (Islam et al., 2010, 2016; Ishaque et al., 2017).
Third, although IGOS included 1000 patients, the num-
bers in some subgroups were small and their analyses had
limited power. Enrolment of patients in IGOS is continu-
ing to overcome this problem. Lastly, patients were clas-
siﬁed according to only one set of electrophysiological
criteria using a single NCS, while the assigned GBS sub-
type depends on the criteria used and may change during
follow-up. The electrophysiology of GBS and performance
of different sets for classiﬁcation will be evaluated in
future dedicated studies.
The standardized collection of data in IGOS has enabled
us to identify differences in the preceding factors, clinical
presentation, neurophysiological classiﬁcation and course
of GBS between regions. In combination with the biosam-
ples collected at the same time, this information will
improve understanding of pathogenesis—involving identiﬁ-
cation of risk factors for GBS, including preceding infec-
tions of which some may be preventable—and allow better
prognostic modelling, adapted to different parts of the
world.
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